# Randomized Controlled Trial of Macrolide Therapy for Mycoplasma pneumoniae

> **NIH NIH R34** · UNIVERSITY OF COLORADO DENVER · 2023 · $266,860

## Abstract

PROJECT SUMMARY
Community-acquired pneumonia (CAP) is the fifth most prevalent but second most costly reason for
hospitalization in children. Mycoplasma pneumoniae (Mp) is the most frequently detected pathogen cause
bacterial CAP. Although macrolides are recommended for the treatment of Mp CAP there is a lack of clear
evidence to support macrolide treatment for Mp has which has likely led to the overuse of macrolides. This R34
application, “Randomized Controlled Trial of Macrolide Therapy for Mp”, will aide in the development of the full
protocol and relevant documents for the future trial. In the future trial, we will randomize children who are
hospitalized with Mp CAP to receive beta-lactam and azithromycin or beta-lactam and placebo. This trial will
provide the necessary evidence for targeted therapy in children hospitalized with Mp CAP, leading to the use of
necessary therapy while preventing over-treatment and decreasing complications for children with this
prevalent disease.

## Key facts

- **NIH application ID:** 10620551
- **Project number:** 1R34AI174969-01
- **Recipient organization:** UNIVERSITY OF COLORADO DENVER
- **Principal Investigator:** Lilliam Ambroggio
- **Activity code:** R34 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $266,860
- **Award type:** 1
- **Project period:** 2023-07-01 → 2025-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10620551

## Citation

> US National Institutes of Health, RePORTER application 10620551, Randomized Controlled Trial of Macrolide Therapy for Mycoplasma pneumoniae (1R34AI174969-01). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10620551. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*